AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24877717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucevia(®) (333 mg per capsule, 3 capsules daily for 3 weeks)
Number of subjects: 22
Study 24877717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucevia(®)
Number of subjects: 22
Study 24877717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 22
Study 22038507 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g/kg ideal body weight/day for 2 months)
Number of subjects: 30
Study 22038507 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (0.5 g/kg ideal body weight/day for 2 months)
Number of subjects: 30
Study 20226365 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy (OMT)
Number of subjects: 50
Study 20226365 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative therapy (CCT)
Number of subjects: 50
Study 17903156 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light phototherapy
Number of subjects: 28
Study 16257842 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (aiming for hemoglobin level 135-160 g/l)
Number of subjects: 12
Study 12153826 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.02-0.06 mg/kg per day)
Number of subjects: 118
Study 12153826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 12153826 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 118
Study 10544910 — intervention group
Group type: EXPERIMENTAL
Intervention: Equidivision method
Number of subjects: 0
Study 10544910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid method
Number of subjects: 0
Study 10544910 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear interpolation
Number of subjects: 0
Study 10544910 — intervention group
Group type: COMPARATOR
Intervention: Control (no deletions)
Number of subjects: 0
Study 8651966 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (5 mg/kg)
Number of subjects: 20
Study 8651966 — intervention group
Group type: COMPARATOR
Intervention: Albumin (5 mg/kg)
Number of subjects: 20
Study 1298577 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrice (0.3% triclosan, 2% methoxyethylene/maleic acid copolymer, 0.243% sodium fluoride/silica base)
Number of subjects: 294
Study 1298577 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 294
Study 6380723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (2 gm intravenously 30 minutes before surgery and four and nine hours after surgery)
Number of subjects: 113
Study 6380723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 113
Study 30849615 — intervention group
Group type: EXPERIMENTAL
Intervention: Online engagement and empowerment intervention
Number of subjects: 182
Study 29669026 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine
Number of subjects: 25
Study 29669026 — intervention group
Group type: COMPARATOR
Intervention: Prototype Ad26.ENVA.01 vaccine
Number of subjects: 25
Study 29669026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28848908 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate delivered by metered dose inhaler (MDI) at doses of 7.2, 9.6, and 19.2 micrograms
Number of subjects: 50
Study 28848908 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate delivered by metered dose inhaler (MDI) at 9.6 micrograms
Number of subjects: 50
Study 28848908 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 50
Study 28848908 — intervention group
Group type: EXPERIMENTAL
Intervention: Foradil(R) 12 micrograms
Number of subjects: 50
Study 24096118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil/finasteride
Number of subjects: 695
Study 24096118 — intervention group
Group type: COMPARATOR
Intervention: Placebo/finasteride
Number of subjects: 695
Study 22641757 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes per day of school physical education for 4 years
Number of subjects: 2395
Study 22641757 — intervention group
Group type: COMPARATOR
Intervention: 60 minutes per week of physical education (control)
Number of subjects: 2395
Study 20418299 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NIPPV) immediately after tracheal extubation
Number of subjects: 40
Study 20418299 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen (standard group)
Number of subjects: 40
Study 17199093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) in fermented milk for 8 weeks
Number of subjects: 0
Study 17199093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) for 8 weeks
Number of subjects: 0
Study 16408815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 600 mg fudosteine
Number of subjects: 36
Study 16408815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg fudosteine
Number of subjects: 36
Study 16408815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg fudosteine
Number of subjects: 36
Study 16408815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of 400 mg fudosteine (3 times a day for 5 days)
Number of subjects: 36
Study 11846497 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic parameters at presentation (Q waves, T-wave inversion, quantitative ST segment changes, initial QRS score)
Number of subjects: 146
Study 9737803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular soluble insulin
Number of subjects: 12
Study 9737803 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous soluble insulin
Number of subjects: 12
Study 9737803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular insulin lispro
Number of subjects: 12
Study 9737803 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin lispro
Number of subjects: 12
Study 8748044 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 35
Study 8748044 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 35
Study 2221971 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor breast milk or standard formula
Number of subjects: 280
Study 2221971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest plasma prolactin concentrations (<1000 mU/l, 32.9 micrograms/l)
Number of subjects: 280
Study 2221971 — intervention group
Group type: COMPARATOR
Intervention: Protein, energy, and mineral enriched preterm formula
Number of subjects: 280
Study 350145 — intervention group
Group type: EXPERIMENTAL
Intervention: Karminomycin 5 mg/m2 daily for 5 days
Number of subjects: 45
Study 350145 — intervention group
Group type: EXPERIMENTAL
Intervention: Karminomycin 6 mg/m2 twice a week for 2-3 weeks
Number of subjects: 45
Study 30471472 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative care program including education sessions and explanatory leaflet on nutrition and physical exercise at home.
Number of subjects: 124
Study 30471472 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control with no intervention).
Number of subjects: 124
Study 28138944 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Rewards program (conditional cash transfer)
Number of subjects: 0
Study 28138944 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26418930 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual eyeglasses
Number of subjects: 42
Study 26418930 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 42
Study 24118468 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anesthesia delivery system (CL group)
Number of subjects: 40
Study 24118468 — intervention group
Group type: COMPARATOR
Intervention: Manual control (manual group)
Number of subjects: 40
Study 21784529 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP‐HFA 100 μg BID
Number of subjects: 63
Study 21784529 — intervention group
Group type: COMPARATOR
Intervention: BDP‐CFC 200 μg BID
Number of subjects: 63
Study 21784529 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP‐HFA 100 μg BID and BDP‐CFC 200 μg BID
Number of subjects: 63
Study 21784529 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP‐HFA
Number of subjects: 63
Study 21784529 — intervention group
Group type: COMPARATOR
Intervention: BDP‐CFC
Number of subjects: 63
Study 19351812 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly physical therapy
Number of subjects: 29
Study 19351812 — intervention group
Group type: COMPARATOR
Intervention: Monthly physical therapy
Number of subjects: 29
Study 16879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle HRT schedule (0.625 mg conjugated estrogen from days 1 to 28 + 5 mg medroxyprogesterone acetate from days 18 to 28) for 2 months (n=25)
Number of subjects: 50
Study 16879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue HRT schedule (0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate from days 1 to 28) for 2 months (n=25)
Number of subjects: 50
Study 15288212 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Number of subjects: 100
Study 15288212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Number of subjects: 100
Study 15288212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Number of subjects: 100
Study 15288212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 100 microg levonorgestrel (EE/LNG)
Number of subjects: 100
Study 11404650 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise plus 60 min/week of jumping rope for 24 months
Number of subjects: 0
Study 11404650 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercisers)
Number of subjects: 0
Study 11404650 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercisers) with OCont
Number of subjects: 0
Study 9227252 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr chloride therapy
Number of subjects: 30
Study 9227252 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy
Number of subjects: 30
Study 8107932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF)
Number of subjects: 42
Study 8107932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-dF)
Number of subjects: 42
Study 2892337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin (50 micrograms sc)
Number of subjects: 10
Study 2892337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28618052 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing of white noise
Number of subjects: 40
Study 28618052 — intervention group
Group type: COMPARATOR
Intervention: Swinging
Number of subjects: 40
Study 27151268 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (n=175)
Number of subjects: 275
Study 25044799 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcaserin 10 mg bid
Number of subjects: 6897
Study 25044799 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6897
Study 22380491 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Electric Vacuum Aspiration (mEVA)
Number of subjects: 94
Study 22380491 — intervention group
Group type: COMPARATOR
Intervention: Sharp Curettage (SC)
Number of subjects: 94
Study 20139793 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (60%-75% observed maximal HR) for > or =45 min.d‐1, 5 d.wk‐1 (n = 87)
Number of subjects: 173
Study 20139793 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group (n = 86)
Number of subjects: 173
Study 18384230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue neuroleptic treatment for 12 months
Number of subjects: 165
Study 18384230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinue treatment)
Number of subjects: 165
Study 15690237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/kg) added to the priming solution of the cardiopulmonary bypass circuit
Number of subjects: 50
Study 15690237 — intervention group
Group type: COMPARATOR
Intervention: No steroids (nonsteroid group)
Number of subjects: 50
Study 11975927 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10367039 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between armspan and height
Number of subjects: 494
Study 10367039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade II vertebral deformities
Number of subjects: 494
Study 10367039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I vertebral deformities
Number of subjects: 494
Study 10367039 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between armspan and height
Number of subjects: 494
Study 10367039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean difference in armspan and height between groups with or without grade II deformities
Number of subjects: 494
Study 7551381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (420 kcal daily high caloric supplement)
Number of subjects: 217
Study 7551381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention + Nandrolone decanoate (25 mg for women, 50 mg for men, injected intramuscularly on Days 1, 15, 29, and 43)
Number of subjects: 217
Study 7551381 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 217
Study 1702132 — intervention group
Group type: EXPERIMENTAL
Intervention: rG‐CSF (2 micrograms/kg/day) for 14 days
Number of subjects: 46
Study 1702132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 963960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous occlusion of all four limbs
Number of subjects: 0
Study 963960 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion to the neck
Number of subjects: 0
Study 963960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous occlusion during immersion
Number of subjects: 0
Study 31784386 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-mm glenosphere
Number of subjects: 82
Study 31784386 — intervention group
Group type: COMPARATOR
Intervention: 38-mm eccentric glenosphere
Number of subjects: 82
Study 31784386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 30880937 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for COPD exacerbation
Number of subjects: 295
Study 30880937 — intervention group
Group type: EXPERIMENTAL
Intervention: EXACT‐PRO assessment
Number of subjects: 295
Study 28099408 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) containing regimens
Number of subjects: 1181
Study 28099408 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) containing regimens
Number of subjects: 1181
Study 28099408 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1181
Study 25827059 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium phosphate and caffeine
Number of subjects: 12
Study 25827059 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium phosphate
Number of subjects: 12
Study 23965255 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention for one year
Number of subjects: 40
Study 23965255 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 40
Study 23965255 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention sustained for one year after withdrawal
Number of subjects: 40
Study 23965255 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control) during PF intervention
Number of subjects: 40
Study 21518564 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 58
Study 21518564 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 58
Study 19841766 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-particle abrasion with alumina particles (50 microm, Al2O3) + silanization
Number of subjects: 60
Study 19841766 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% hydrofluoric acid (HF) for 90 s + silanization
Number of subjects: 60
Study 19841766 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrestored teeth)
Number of subjects: 60
Study 17154781 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing the task from the actor's perspective
Number of subjects: 0
Study 17154781 — intervention group
Group type: COMPARATOR
Intervention: Describing the task from the observer's own perspective or another observer's perspective
Number of subjects: 0
Study 15570142 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of casein (CS)
Number of subjects: 23
Study 15570142 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey proteins (WH)
Number of subjects: 23
Study 15570142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study 11154543 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment instrumentation with transpedicular grafting (TPG) (n = 10)
Number of subjects: 20
Study 11154543 — intervention group
Group type: COMPARATOR
Intervention: Short-segment fixation alone (NTPG) (n = 10)
Number of subjects: 20
Study 9135492 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 60 mg/m2/24 h (total dose for cycle 180 mg/m2) days 1, 2 and 3 (group A)
Number of subjects: 106
Study 9135492 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2/24 h days 1, 2 and 3 and cisplatin 30 mg/m2/24 h days 2, 3, 4 and 5 (group B)
Number of subjects: 106
Study 7703994 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy
Number of subjects: 16
Study 7703994 — intervention group
Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 16
Study 3328681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 75 micrograms in 0.9% saline
Number of subjects: 20
Study 3328681 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2 mg
Number of subjects: 20
Study 30361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus/reduced tacrolimus (EVR/rTAC)
Number of subjects: 716
Study 30361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with tacrolimus discontinued (TAC Elimination)
Number of subjects: 716
Study 30361470 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC Control)
Number of subjects: 716
Study 30361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative eGFR AUC
Number of subjects: 716
Study 30361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean eGFR AUC
Number of subjects: 716
Study 27152748 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg IV-ibuprofen every 6 hours
Number of subjects: 206
Study 27152748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 27152748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study 26224300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 115
Study 26224300 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 115
Study 23085508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 25
Study 23085508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20807467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Na high-K (LNAHK) diet
Number of subjects: 94
Study 20807467 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-type diet
Number of subjects: 94
Study 20807467 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 94
Study 18462291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention regime for early periodontal disease
Number of subjects: 109
Study 18462291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study 16428570 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg lidocaine + 8 mg dexamethasone
Number of subjects: 75
Study 16428570 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg lidocaine
Number of subjects: 75
Study 16428570 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg lidocaine for IVRA and 8 mg dexamethasone IV to the nonsurgical arm
Number of subjects: 75
Study 15571445 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives contingent on abstinence (CO +/‐ 4 ppm)
Number of subjects: 34
Study 15571445 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent monetary incentives
Number of subjects: 34
Study 15571445 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group
Number of subjects: 34
Study 11705560 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 317
Study 11705560 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 317
Study 9354316 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 3 days
Number of subjects: 8
Study 9354316 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 3 days
Number of subjects: 8
Study 8131469 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-directed weaning system
Number of subjects: 15
Study 8131469 — intervention group
Group type: COMPARATOR
Intervention: Physician-controlled weaning
Number of subjects: 15
Study 3592401 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 ppm formaldehyde
Number of subjects: 38
Study 3592401 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 38
Study 31666831 — intervention group
Group type: COMPARATOR
Intervention: Standard Dressing (SD)
Number of subjects: 60
Study 31666831 — intervention group
Group type: COMPARATOR
Intervention: Aspiration Drainage (AD)
Number of subjects: 60
Study 31666831 — intervention group
Group type: COMPARATOR
Intervention: Negative-Pressure (NP)
Number of subjects: 60
Study 28628356 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips (GI)
Number of subjects: 30
Study 28628356 — intervention group
Group type: COMPARATOR
Intervention: Silicone-resilient liner (GII)
Number of subjects: 30